SAN DIEGO — Gen-Probe’s (NASDAQ: GPRO) multiple new product launches are off to a good start and should help drive accelerating, double-digit revenue growth in 2012, according to Carl Hull, Gen-Probe’s chairman and CEO, who will discuss the Company’s 2011 accomplishments and future strategies with investors at JP Morgan’s 30th annual healthcare conference in San Francisco beginning today.

“2012 is a very exciting and important year for Gen-Probe, as we add multiple new products to our already strong franchises in STD testing and blood screening to accelerate top-line growth,” Hull said. “At the same time, we plan to lay the foundation for sustainable, long-term growth by investing in attractive new product opportunities where our core capabilities and customer relationships provide competitive advantage.”

At the conference, Gen-Probe plans to discuss these business developments with investors:

The Company achieved its goal of placing a few dozen PANTHER® systems with diagnostics customers outside the United States in 2011, with PANTHER-related revenues adding progressively more to growth over the course of the year.

The Company’s R&D priorities for 2012 include two significant instrument development programs that leverage the Company’s automation expertise and intellectual property: adding real-time PCR capabilities for the next-generation PANTHER system, and developing a new instrument to further automate molecular testing from liquid-based cytology specimens.

The Company has already recorded its first commercial sales of the APTIMA® HPV assay, and is pleased with the high level of customer interest to date.

More than 80 customers have adopted or are evaluating the APTIMA trichomonas assay, sales of which have increased on a sequential basis throughout 2011.

The Company recently launched its CE-marked APTIMA trichomonas assay on the PANTHER system in Europe.

Gen-Probe’s presentation for the JP Morgan conference will be available at https://phx.corporate-ir.net/phoenix.zhtml?c=135117&p=irol-presentations. A live webcast will be available at the same location at 2 pm Pacific Time on January 10.

About Gen-Probe

Gen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility. Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to https://www.gen-probe.com.